CN114105977A - Estrogen receptor modulator compounds and uses thereof - Google Patents

Estrogen receptor modulator compounds and uses thereof Download PDF

Info

Publication number
CN114105977A
CN114105977A CN202110997502.6A CN202110997502A CN114105977A CN 114105977 A CN114105977 A CN 114105977A CN 202110997502 A CN202110997502 A CN 202110997502A CN 114105977 A CN114105977 A CN 114105977A
Authority
CN
China
Prior art keywords
cycloalkyl
radical
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110997502.6A
Other languages
Chinese (zh)
Other versions
CN114105977B (en
Inventor
张雁
杨圣伟
庞司林
唐锋
王峰
彭少平
任晋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Xiansheng Zaiming Pharmaceutical Co ltd
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Publication of CN114105977A publication Critical patent/CN114105977A/en
Application granted granted Critical
Publication of CN114105977B publication Critical patent/CN114105977B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds having estrogen receptor modulating activity or function and pharmaceutically acceptable salts thereof are described, having the structure of formula (I) and having the substituents and structural features described herein. Also described are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of an estrogen receptor related disorder.

Description

Estrogen receptor modulator compounds and uses thereof
The present application claims priority from a prior application entitled "estrogen receptor modulator compounds and uses thereof" filed on 28.8.2020, patent application No. 202010886642.1 by the national intellectual property office. The entire contents of said prior application are incorporated by reference into the present application.
Technical Field
The present invention relates to an estrogen receptor modulator compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and use thereof in preventing or treating estrogen receptor related diseases.
Background
Estrogen (E2) and estrogen α receptor (era) are important drivers of the development of breast cancer. In breast cancer patients over 2/3 express ER transcription factors, and in most ER-positive patients, ER remains a key driver even in tumors that progress after early endocrine therapy, and thus ER is a major target for breast cancer therapy (Pharmacology & Therapeutics 186(2018) 1-24). Endocrine therapy, aimed at reducing ER activity, is mainly divided into three classes, including Selective Estrogen Receptor Modulators (SERMs), such as tamoxifen (tamoxifen), which are allosteric modulators of the ER that inhibit its transcriptional activity when bound to the ER; aromatase Inhibitors (AIs) reduce the level of estrogen in the body by inhibiting the conversion of androgens to estrogens; and selective estrogen receptor down-regulators, such as fulvestrant (fulvestrant), not only act as an antagonist of ER inhibiting its activity, but also have the effect of inducing ER protein degradation. Although endocrine therapy is the first choice for estrogen receptor positive breast cancer patients, approximately 30% of post-treatment patients relapse and almost all metastatic breast cancer patients develop resistance to progress. Two main mechanisms for generating drug resistance in endocrine treatment are that the endocrine treatment focuses on an estrogen receptor signal pathway, including activation mutation, amplification and fusion with other genes of ESR1, an estrogen receptor co-regulatory factor, disorder of a downstream control cell cycle factor and the like; another class of mechanisms involves the activation of signaling pathways that cross-react with estrogen receptor signaling pathways, such as the growth factor receptor pathway, etc. (Oncol Ther, 2017,5: 17-29).
Fulvestrant is the first and only clinically approved Selective Estrogen Receptor Downregulator (SERDs) class of drugs for post-menopausal patients in the treatment of ER positive, metastatic breast cancer following tamoxifen or aromatase inhibitor progression. In addition, a series of SERDs with novel structures and corresponding medical application are disclosed by Asricon (see patent application WO2018077630A1) and Genetake (see patent application WO2019245974A 1). Multiple study data show that degradation of ER is not fully achieved in fulvestrant-treated patients, but it is also possible that fulvestrant doses (up to 500mg, primarily its pharmacodynamic profile and intramuscular route of administration limit the maximum dose that can be administered to patients) limit its efficacy. Therefore, there is a clinical need for SERDs with improved bioavailability, improved ER antagonism, greater ER degradation, and ease of oral administration that can be used in premenopausal patients with elevated estrogen levels.
Disclosure of Invention
The invention relates to a compound shown as a formula (I) or a pharmaceutically acceptable salt thereof:
Figure BDA0003234344130000011
wherein,
X1、X2、X3、X4independently selected from CR7Or N;
R7selected from H, F, Cl, Br, I, OH, CN, C1-C6Alkyl radical, C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C1-C6Alkoxy radical, C3-C6Cycloalkyloxy or 3-6 membered heterocycloalkyloxy;
het is selected from
Figure BDA0003234344130000021
R1、R2Independently selected from hydrogen, OH, F, Cl, Br, I, C1-C6Alkyl or C2-C8An alkenyl group;
or, R1、R2Together with the carbon atom to which they are attached form C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with RaSubstitution;
w is selected from the group consisting of C in linear or branched form1-C3An alkylene group;
R5is selected from C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
R6Selected from H, C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
R3Selected from H, CN, COOH, C (O) ORb、OC(O)Rb、CONH2、C(O)NRbRc、SO2Rb、SO2NRbRc、C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl radical, C3-C6Heterocycloalkyl radical, C6-C10Aryl or C5-C10Heteroaryl of said C1-C6Alkyl radical, C3-C6Cycloalkyl radical, C3-C6Heterocycloalkyl radical, C6-C10Aryl or C5-C10Heteroaryl is optionally substituted with 1 or more RdSubstitution;
R4selected from H, F, Cl, Br, I, OH, C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl or C3-C6Heterocycloalkyl radical of said C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl or C3-C6Heterocycloalkyl is optionally substituted with one or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
Ring Q is selected from C6-C10Aryl or 5-to 10-membered heteroaryl, said C6-C10Aryl or 5-10 membered heteroaryl optionally substituted with 1 or more R8Substitution;
R8selected from F, Cl, Br, I, OH, CN, COOH, C (O) ORb、OC(O)Rb、CONH2、C(O)NRbRc、NRcC(O)Rb、SO2Rb、SO2NRb、C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C6-C10Aryl or 5-to 10-membered heteroaryl, said C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C6-C10Aryl or 5-10 membered heteroaryl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, OH, CN, C1-C6Alkyl and C1-C6An alkoxy group;
Raselected from halogen, OH, CN, C1-6Alkyl radical, C1-6Alkoxy radical, C3-6Cycloalkyl or 3-6 membered heterocycloalkyl, said C1-6Alkyl radical, C1-6Alkoxy radical, C3-6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with halogen;
Rbis independently selected from C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C6-C10Aryl or 5-10 membered heteroaryl;
Rcindependently selected from H, C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C6-C10Aryl or 5-10 membered heteroaryl;
Rdindependently selected from F, Cl, Br, I, OH, CN, C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with 1 or more groups selected from F, Cl, Br, I or OH;
n is 0, 1 or 2.
In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt thereof, is selected from a compound of formula (Ia), or a pharmaceutically acceptable salt thereof:
Figure BDA0003234344130000031
in some embodiments, the R is1、R2Together with the carbon atom to which they are attached form C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with RaAnd (4) substitution.
In some embodiments, the R is1、R2Together with the carbon atom to which they are attached form C3-C4Cycloalkyl or 3-4 membered heterocycleAlkyl radical, said C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with RaAnd (4) substitution.
In some embodiments, the R is1、R2Together with the carbon atom to which they are attached form a cyclopropane.
In some embodiments, the R is1、R2Independently selected from hydrogen, OH, F, Cl, Br, I, C1-C6Alkyl or C2-C8An alkenyl group.
In some embodiments, the R is1、R2Independently selected from hydrogen, OH, F, Cl, Br or I.
In some embodiments, the R is1、R2Selected from hydrogen.
In some embodiments, the n is selected from 0 or 1.
In some embodiments, the n is selected from 0.
In some embodiments, the R is3Is selected from C1-C6Alkyl, CN, COOH, C (O) ORb、OC(O)Rb、CONH2、C(O)NRbRcOr C6-C10Aryl radical, said C1-C6Alkyl or C6-C10Aryl is optionally substituted by one or more RdSubstituted, RdIndependently selected from F, Cl, Br, I, OH, CN or C optionally substituted with 1 or more groups selected from F, Cl, Br, I or OH1-C6An alkyl group.
In some embodiments, the R is3Is selected from C1-C6Alkyl or C6-C10Aryl radical, said C1-C6Alkyl or C6-C10Aryl is optionally substituted by one or more RdSubstituted, RdIndependently selected from F, Cl, Br, OH or C optionally substituted with 1 or more groups selected from F, Cl, Br or OH1-C6An alkyl group.
In some embodiments, the R is3Is selected from C1-C3Alkyl radical, said C1-C3Alkyl is optionally substituted by one or more RdSubstituted, RdIndependently selected from F or OH.
In some embodiments, the R is3Is selected from-CH2CF3Or
Figure BDA0003234344130000032
In some embodiments, the R is3Is selected from
Figure BDA0003234344130000033
In some embodiments, the R is4Selected from C optionally substituted by F, Cl, Br or I1-C6An alkyl group.
In some embodiments, the R is4Selected from methyl optionally substituted with F, Cl, Br or I.
In some embodiments, the R is4Is methyl.
In some embodiments, the W is selected from the linear form of C1-C3An alkylene group.
In some embodiments, the W is selected from-CH2-or-CH2CH2-。
In some embodiments, the W is selected from-CH2-。
In some embodiments, the R is5Is C3-C6Cycloalkyl radical, said C3-C6Cycloalkyl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
In some embodiments, the R is5Is C3-C5Cycloalkyl radical, said C3-C5Cycloalkyl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
In some embodiments, the R is5Is cyclopropyl or cyclobutyl, optionally substituted by 1 or more groups selected from: F. cl, Br, I,CN、OH、OCH3And SO2CH3
In some embodiments, the R is5Is cyclopropyl or cyclobutyl, optionally substituted by 1 or more groups selected from: F. cl, Br, I and CN.
In some embodiments, the R is5Is cyclopropyl or cyclobutyl, optionally substituted by 1 or more groups selected from: F. cl, Br and I.
In some embodiments, the R is5Is composed of
Figure BDA0003234344130000041
In some embodiments, said X is1、X4Selected from the group consisting of CR7Or N, X2、X3Is CR7
In some embodiments, the R is7Selected from H, F, Cl, Br or I.
In some embodiments, said X is1、X4Selected from CH, CF or N, X2、X3Is CH.
In some embodiments, said X is1、X4Is CF, X2、X3Is CH.
In some embodiments, said X is1Is N, X2、X3、X4Is CH.
In some embodiments, the R is6Is selected from H or C1-C6An alkyl group.
In some embodiments, the R is6Is selected from H.
In some embodiments, when Het is associated with NR6When the connected atom is a chiral carbon, the configuration is (S) -configuration.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (II) or a pharmaceutically acceptable salt thereof:
Figure BDA0003234344130000042
wherein X1、X2、X3、X4、Het、R3、R4And R6As defined for formula (I);
R10selected from H, C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
In some embodiments, R10Selected from H, C1-C6Alkyl radical, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl.
In some embodiments, R10Is H.
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (IIa) or a pharmaceutically acceptable salt thereof:
Figure BDA0003234344130000043
wherein X1、X2、X3、X4、Het、R3、R4、R6And R10As defined in formula (II).
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (III):
Figure BDA0003234344130000051
wherein X1、X2、X3、X4、Het、R3、R4And R6As defined in formula (I).
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (IIIa) or a pharmaceutically acceptable salt thereof:
Figure BDA0003234344130000052
wherein X1、X2、X3、X4、Het、R3、R4And R6As defined in formula (I).
In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from the following compounds or pharmaceutically acceptable salts thereof:
Figure BDA0003234344130000053
Figure BDA0003234344130000061
in one aspect, the compounds described herein exist as a racemic mixture or in enantiomerically enriched or enantiomerically pure form. In certain embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compounds with an optically active resolving agent to form a pair of diastereomeric compounds/salts, separating the diastereomers and recovering the enantiomers in optical purity. In some embodiments, resolution of enantiomers is performed using covalent diastereomeric derivatives of the compounds described herein. In another embodiment, the diastereomers are separated by separation/resolution techniques based on solubility differences. In certain embodiments, the compounds described herein are prepared as their individual stereoisomers by enzymatic resolution. In some embodiments, resolution of individual stereoisomers is performed using a lipase or esterase. In some embodiments, resolution of individual stereoisomers is performed by lipase or esterase catalyzed asymmetric deacylation. In other embodiments, separation of stereoisomers is performed by chromatography, or by forming salts of diastereomers and separating by recrystallization or chromatography, or any combination thereof. In some embodiments, the stereoisomers are obtained by stereoselective synthesis.
The invention also provides a pharmaceutical composition which comprises the compound shown in the formula (I) or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and/or excipient.
In some embodiments, the pharmaceutical composition is formulated for intravenous injection, subcutaneous injection, oral administration, or topical administration.
In some embodiments, the pharmaceutical composition is a tablet, pill, capsule, liquid, suspension, gel, dispersion, solution, emulsion, ointment, or lotion.
Further, the invention relates to an application of the compound shown in the formula (I) or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preparing a medicament for preventing or treating estrogen receptor related diseases.
Further, the invention relates to a compound shown in a formula (I) or pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof, which is used for preventing or treating estrogen receptor related diseases.
Further, the invention relates to an application of the compound shown in the formula (I) or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preventing or treating estrogen receptor related diseases.
Further, the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for preventing or treating an estrogen receptor related disease.
The invention also relates to a method for treating estrogen receptor related diseases, which comprises administering a therapeutically effective dose of a pharmaceutical preparation containing the compound shown in the formula (I) or the pharmaceutically acceptable salt thereof to a patient.
The present invention also relates to a method of treating estrogen receptor related disorders in a mammal, comprising administering to a mammal, preferably a human, in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
The preferred embodiment of the present invention, wherein the estrogen receptor related diseases include but are not limited to cancer, autoimmune diseases and the like.
In some embodiments of the invention, the estrogen receptor related disorder is preferably a tumor.
In some embodiments of the invention, the estrogen receptor related disorder includes, but is not limited to, breast cancer.
Definition and description of terms
Unless otherwise indicated, the definitions of groups and terms described in the specification and claims of the present invention, including definitions thereof as examples, exemplary definitions, preferred definitions, definitions described in tables, definitions of specific compounds in the examples, and the like, may be arbitrarily combined and coupled with each other. The definitions of the groups and the structures of the compounds in such combinations and after the combination are within the scope of the present invention as defined in the specification. A particular term should not be considered as ambiguous or unclear without special definition, but rather construed according to ordinary meaning in the art. When a trade name appears herein, it is intended to refer to its corresponding commodity or its active ingredient.
In this context
Figure BDA0003234344130000071
Indicates the attachment site.
The term "stereoisomer" refers to isomers resulting from the different arrangement of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers, and conformers.
The compounds of the present invention may have an asymmetric atom such as a carbon atom, a sulfur atom, a nitrogen atom, a phosphorus atom or an asymmetric double bond, and thus the compounds of the present invention may exist in a specific geometric or stereoisomeric form. The particular geometric or stereoisomeric forms may be the cis and trans isomers, the E and Z geometric isomers, the (-) -and (+) -enantiomers, (R) -and (S) -enantiomers, diastereomers, (D) -isomers, (L) -isomers, as well as racemic or other mixtures thereof, e.g., enantiomerically or diastereomerically enriched mixtures, all of which, as well as mixtures thereof, are within the definition of the compounds of the present invention. The presence of additional asymmetric carbon, sulfur, nitrogen or phosphorus atoms in substituents such as alkyl groups is also within the definition of the compounds of the invention as regards all such isomers and mixtures thereof. The compounds of the invention containing asymmetric atoms can be isolated in optically pure form or in racemic form, the optically pure form can be resolved from a racemic mixture, or synthesized by using chiral starting materials or chiral reagents.
The enantiomers or enantiomerically pure compounds herein are illustrated by Maehr, J.chem.Ed.1985, 62: 114-120. Using wedge and dashed bonds, unless otherwise indicated (
Figure BDA0003234344130000081
And
Figure BDA0003234344130000082
) Indicating the absolute configuration of a stereocenter. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, they include the E, Z geometric isomer unless otherwise specified. Likewise, all tautomeric forms are included within the scope of the invention.
The term "tautomer" refers to an isomer of a functional group resulting from the rapid movement of an atom in two positions in a molecule. The compounds of the invention may exhibit tautomerism. Tautomeric compounds may exist in two or more interconvertible species. Tautomers generally exist in equilibrium, and attempts to isolate a single tautomer often result in a mixture whose physicochemical properties are consistent with the mixture of compounds. The position of equilibrium depends on the chemical properties within the molecule. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the keto form predominates; whereas in phenol the enol type predominates. The present invention encompasses all tautomeric forms of the compounds.
The term "substituted" means that any one or more hydrogen atoms on a particular atom is replaced with a substituent, so long as the valence of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e., ═ O), meaning that two hydrogen atoms are substituted, oxo does not occur on the aryl.
The terms "optionally" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, ethyl is "optionally" substituted with halo, meaning that ethyl may be unsubstituted (CH)2CH3) Monosubstituted (e.g. CH)2CH2F) Polysubstituted (e.g. CHFCH)2F、CH2CHF2Etc.) or completely substituted (CF)2CF3). It will be appreciated by those skilled in the art that any group containing one or more substituents will not incorporate any substitution or substitution pattern which is sterically impossible and/or cannot be synthesized.
The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.
Herein Cm-CnRefers to having an integer number of carbon atoms in the range of m-n. E.g. "C1-C10By "is meant that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, or 10 carbon atoms.
The term "alkyl" refers to a group of formula CnH2n+1The alkyl group may be linear or branched. The term "C1-C6Alkyl "is understood to mean a straight-chain or branched, saturated monovalent hydrocarbon radical having 1,2,3, 4,5, 6 carbon atoms. The alkyl group is as followsSuch as methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-ethylpropyl, 1, 2-dimethylpropyl, neopentyl, 1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 2, 3-dimethylbutyl, 1, 3-dimethylbutyl, or 1, 2-dimethylbutyl, and the like.
The term "alkoxy" refers to a monovalent radical derived from a straight or branched chain alcohol by loss of a hydrogen atom from a hydroxyl group, and is understood to mean an "-O-alkyl". According to the invention, suitable alkoxy is C1-6Alkoxy radicals, e.g. C1-5Alkoxy radical, C1-4Alkoxy radical, C1-3Alkoxy groups, including methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, sec-butoxy, and the like.
The term "alkenyl" refers to an unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms, which is straight or branched, and has at least one double bond. The term "C2-C8Alkenyl "is understood to preferably mean a straight-chain or branched monovalent hydrocarbon radical which contains one or more double bonds and has 2,3,4, 5, 6,7 or 8 carbon atoms.
The term "alkynyl" refers to a straight or branched chain unsaturated aliphatic hydrocarbon group having at least one triple bond composed of carbon atoms and hydrogen atoms. The term "C2-C4Alkynyl "is understood as preferably meaning a straight-chain or branched, monovalent hydrocarbon radical which contains one or more triple bonds and has 2,3 or 4 carbon atoms.
The term "cycloalkyl" refers to a carbon ring that is fully saturated and exists as a single ring, a bicyclic ring, a bridged ring, or a spiro ring, among others. Unless otherwise indicated, the carbocycle is typically a 3 to 10 membered ring. The term "C3-C6Cycloalkyl "is understood to mean a saturated, monovalent, monocyclic or bicyclic hydrocarbon ring having 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The term "C3-C5Cycloalkyl is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbonA ring having 3 to 5 carbon atoms, such as cyclopropyl, cyclobutyl or cyclopentyl.
The term "heterocycloalkyl" refers to a cyclic group that is fully saturated and may exist as a single ring, a bridged ring, or a spiro ring. Unless otherwise indicated, the heterocyclic ring is typically a 3 to 7 membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen and/or nitrogen. The term "3-6 membered heterocycloalkyl" refers to heterocycloalkyl groups having 3,4, 5, 6 ring atoms, respectively. Examples of 3-membered heterocycloalkyl include, but are not limited to, oxiranyl, thietanyl, cycloazenyl, non-limiting examples of 4-membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, examples of 5-membered heterocycloalkyl include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl, tetrahydropyrazolyl, examples of 6-membered heterocycloalkyl include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, piperazinyl, 1, 4-thiaxanyl, 1, 4-dioxanyl, thiomorpholinyl, 1, 3-dithianyl, 1, 4-dithianyl, and the like.
The term "aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated pi-electron system. The term "C6-C10Aryl "is understood to preferably mean a monocyclic or bicyclic hydrocarbon ring of monovalent aromaticity having from 6 to 10 carbon atoms. In particular a ring having 6 carbon atoms ("C)6Aryl "), such as phenyl; or a ring having 9 carbon atoms ("C)9Aryl group), such as indanyl or indenyl, or a ring having 10 carbon atoms ("C)10Aryl), such as tetralinyl, dihydronaphthyl, or naphthyl.
The term "heteroaryl" refers to a monocyclic or fused polycyclic aromatic ring system containing at least one ring atom selected from N, O, S, the remaining ring atoms being C. The term "5-to 10-membered heteroaryl" is understood to include such monovalent monocyclic or bicyclic aromatic ring systems: having 5 to 10 ring atoms and comprising 1 to 5 heteroatoms independently selected from N, O and S. The term "5-to 10-membered heteroaryl" is understood to include such monovalent monocyclic or bicyclic aromatic ring systems: which has 5, 6,7,8,9, 10 ring atoms, in particular 5 or 6 or 9 or 10 ring atoms, and which comprises 1 to 5, preferably 1 to 3, heteroatoms each independently selected from N, O and S and, in addition, can be benzo-fused in each case. In particular, the heteroaryl group is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, 1,2, 3-triazolyl, 1,2, 4-triazolyl, thiadiazolyl and the like and their benzo derivatives, such as benzofuryl, benzothienyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like, and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl, and the like; or azocinyl, indolizinyl, purinyl and the like and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and the like.
The term "therapeutically effective amount" means an amount of a compound of the invention that (i) treats or prevents a particular disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of a compound of the present invention that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art with their own knowledge and this disclosure.
The term "pharmaceutically acceptable" is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term "pharmaceutically acceptable salts" refers to pharmaceutically acceptable salts of non-toxic acids or bases, including salts of inorganic acids and bases, organic acids and bases.
The term "adjuvant" refers to a pharmaceutically acceptable inert ingredient. Examples of classes of the term "excipient" include, without limitation, binders, disintegrants, lubricants, glidants, stabilizers, fillers, diluents, and the like. Excipients enhance the handling characteristics of the pharmaceutical formulation, i.e., make the formulation more amenable to direct compression by increasing flowability and/or cohesiveness. Examples of typical "pharmaceutically acceptable carriers" suitable for use in the above formulations are: saccharides, starches, cellulose and its derivatives and the like are commonly used as excipients in pharmaceutical preparations.
The term "pharmaceutical composition" denotes a mixture of one or more compounds described herein or a physiologically/pharmaceutically acceptable salt or prodrug thereof with other chemical components, such as physiologically/pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to facilitate the administration of the compound to an organism.
The words "comprise", "comprises", "comprising" or "including" and variations thereof such as "comprises" or "comprising" are to be interpreted in an open, non-exclusive sense, i.e., "including but not limited to".
The pharmaceutical composition of the present invention can be prepared by combining the compound of the present invention with suitable pharmaceutically acceptable excipients, and can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, pastes, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres, aerosols, and the like.
Typical routes of administration of the compounds of the present invention or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, intravenous administration.
The pharmaceutical compositions of the present invention may be manufactured by methods well known in the art, such as conventional mixing, dissolving, granulating, emulsifying, lyophilizing, and the like.
In some embodiments, the pharmaceutical composition is in an oral form. For oral administration, the pharmaceutical compositions may be formulated by mixing the active compounds with pharmaceutically acceptable excipients well known in the art. These adjuvants enable the compounds of the present invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, slurries, suspensions and the like, for oral administration to a patient.
Solid oral compositions may be prepared by conventional mixing, filling or tableting methods. For example, it can be obtained by the following method: the active compounds are mixed with solid adjuvants, optionally the mixture obtained is milled, if desired with further suitable adjuvants, and the mixture is then processed to granules, to give tablets or dragee cores. Suitable excipients include, but are not limited to: binders, diluents, disintegrants, lubricants, glidants or flavoring agents, and the like.
The pharmaceutical compositions may also be adapted for parenteral administration, as sterile solutions, suspensions or lyophilized products in suitable unit dosage forms.
In all methods of administration of the compounds of formula (I) described herein, the daily dose is from 0.01mg/kg to 200mg/kg body weight, preferably from 0.05mg/kg to 50mg/kg body weight, more preferably from 0.1mg/kg to 30mg/kg body weight, in single or divided doses.
The invention also includes isotopically-labeled compounds of the present invention, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine, such as respectively2H、3H、11C、13C、14C、13N、15N、15O、17O、18O、31P、32P、35S、18F、123I、125I and36cl, and the like.
Certain isotopically labelledCompounds of the invention (e.g. with3H and14c-label) can be used in compound and/or substrate tissue distribution assays. Tritiated (i.e. by tritiation)3H) And carbon-14 (i.e.14C) Isotopes are particularly preferred for their ease of preparation and detectability. Positron emitting isotopes, such as15O、13N、11C and18f can be used in Positron Emission Tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the schemes and/or in the examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
The term "IC50"is the half maximal inhibitory concentration, and refers to the concentration of a particular compound required to obtain 50% inhibition of a biological process in vitro. IC (integrated circuit)50The values can be logarithmically converted into pIC50Value (-log IC)50) Wherein a higher value indicates a greater efficacy in an exponential manner.
The compounds of the present invention may be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combinations thereof with other chemical synthetic methods, and equivalents thereof known to those skilled in the art, with preferred embodiments including, but not limited to, examples of the present invention.
The chemical reactions of the embodiments of the present invention are carried out in a suitable solvent that is compatible with the chemical changes of the present invention and the reagents and materials required therefor. In order to obtain the compounds of the present invention, it is sometimes necessary for a person skilled in the art to modify or select the synthesis steps or reaction schemes based on the existing embodiments.
For clarity, the present application is further illustrated by examples, which do not limit the scope of the present application. All reagents used herein were commercially available and used without further purification.
Detailed Description
The following examples illustrate the technical solutions of the present invention in detail, but the scope of the present invention includes but is not limited thereto. Having described the invention in detail and having disclosed specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
The structure of the compounds is determined by Nuclear Magnetic Resonance (NMR) and/or Mass Spectrometry (MS). NMR shift in units of 10-6(ppm). Solvents for NMR measurement were deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol, etc., and an internal standard was Tetramethylsilane (TMS).
Example 1: 3- (((1R, 3R) -1- (2, 6-difluoro-4- ((1- ((((1R, 2R) -2-fluorocyclopropyl) methyl) azetidin-3-yl) amino) phenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000111
Step 1: synthesis of 5-bromo-2- (diethoxymethyl) -1, 3-difluorobenzene
Figure BDA0003234344130000112
4-bromo-2, 6-difluorobenzaldehyde (2.19g, 10.0mmol) was added to 50mL of ethanol, triethyl orthoformate (1.48g, 10.0mmol) was added dropwise, 1 drop of concentrated sulfuric acid was added dropwise and the mixture was heated to 60 ℃ with stirring, after 4 hours the reaction was complete, and the reaction was spin-dried to obtain the title compound.
Step 2: synthesis of tert-butyl 3- (((4- (diethoxymethyl) -3, 5-difluorophenyl) amino) azetidine-1-carboxylate
Figure BDA0003234344130000113
5-bromo-2- (diethoxymethyl) -1, 3-difluorobenzene (2.94g, 10.0mmol), 1-tert-butoxycarbonyl-3-aminocyclobutylamine (2.06g, 12.0mmol), tris (dibenzylideneacetone) dipalladium (458mg, 0.5mmol), 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (579mg, 1.00mmol), cesium carbonate (9.75g,30.0mmol) were added to 40mL1, 4-dioxane, heated to 80 ℃ under argon protection, stirred for 6 hours, and after completion of the reaction, the reaction solution was concentrated, 100mL ethyl acetate was added, suction filtered, and the filtrate was concentrated to give a crude product.
And step 3: synthesis of tert-butyl 3- ((3, 5-difluoro-4-formylphenyl) amino) azetidine-1-carboxylate
Figure BDA0003234344130000114
And (3) adding the crude product obtained in the last step into 50mL of tetrahydrofuran, adding 20mL of 2N diluted hydrochloric acid solution, stirring at room temperature, reacting after 2 hours, adjusting the pH of the reaction solution to 8-9 by using saturated sodium bicarbonate aqueous solution, adding 50mL of water, extracting by using ethyl acetate, combining organic layers, concentrating, and performing column chromatography to obtain the title compound.
And 4, step 4: synthesis of tert-butyl 3- ((4- ((1R, 3R) -2- (2, 2-difluoro-3-hydroxypropyl) -3-methyl-2, 3,4, 9-tetrahydro-1H-pyridinyl [3,4-b ] indol-1-yl) -3, 5-difluorophenyl) amino) azetidine-1-carboxylate
Figure BDA0003234344130000121
Adding tert-butyl 3- ((3, 5-difluoro-4-formylphenyl) amino) azetidine-1-carboxylate (2.50g, 8.00mmol), (R) -3- (((1- (1H-indol-3-yl) propan-2-yl) amino) -2, 2-difluoropropan-1-ol (2.18g, 8.00mmol) to 40mL of toluene, adding 4mL of acetic acid, heating to 80 ℃, stirring for 20 hours, then after the reaction is completed, concentrating the reaction solution, adding 100mL of water, adjusting the pH to 8-9 with a saturated sodium bicarbonate solution, extracting with ethyl acetate, combining organic layers, concentrating, and performing column chromatography to obtain the title compound.
And 5: synthesis of 3- ((1R, 3R) -1- (4- (azetidin-3-ylamino) -2, 6-difluorophenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyridinyl [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000122
3- ((1R, 3R) -1- (4- (azetidin-3-ylamino) -2, 6-difluorophenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyridinyl [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol (2.88g, 5.12mmol) was dissolved in 30mL of tetrahydrofuran, cooling to 0 ℃, slowly dropwise adding concentrated sulfuric acid (2.78mL, 52.0mmol), transferring to room temperature after dropwise addition, stirring for 2 hours, then finishing reaction, cooling the reaction liquid to 0 ℃, slowly dropwise adding a saturated sodium bicarbonate aqueous solution, adjusting the pH to 8-9, adding 50mL of water, extracting with ethyl acetate, combining organic layers, drying with anhydrous sodium sulfate, and concentrating after suction filtration to obtain the title compound.
Step 6: synthesis of (3- ((4- ((1R, 3R) -2- (2, 2-difluoro-3-hydroxypropyl) -3-methyl-2, 3,4, 9-tetrahydro-1H-pyridinyl [3,4-b ] indol-1-yl) -3, 5-difluorophenyl) amino) azetidin-1-yl) ((1R, 2R) -2-fluorocyclopropyl) methanone
Figure BDA0003234344130000123
3- ((1R, 3R) -1- (4- (azetidin-3-ylamino) -2, 6-difluorophenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyridinyl [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol (2.34g, 5.06mmol), 2- (7-azabenzotriazole) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (2.30g, 6.07mmol), (1R, 2R) -2-fluorocyclopropane-1-carboxylic acid (526mg, 5.06mmol) were dissolved in 30mL of N, N-dimethylformamide, N, N-diisopropylethylamine (1.96g, 15.2mmol) was stirred at room temperature for 1 hour, the reaction was completed, the reaction solution was added to 100mL of water, extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to obtain the title compound.
And 7: synthesis of 3- (((1R, 3R) -1- (2, 6-difluoro-4- ((1- ((((1R, 2R) -2-fluorocyclopropyl) methyl) azetidin-3-yl) amino) phenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000131
(3- ((4- ((1R, 3R) -2- (2, 2-difluoro-3-hydroxypropyl) -3-methyl-2, 3,4, 9-tetrahydro-1H-pyridinyl [3,4-b ] indol-1-yl) -3, 5-difluorophenyl) amino) azetidin-1-yl) ((1R, 2R) -2-fluorocyclopropyl) methanone (0.60g, 1.09mmol) was added to 10mL anhydrous tetrahydrofuran, cooling to 0 ℃, slowly dropwise adding a tetrahydrofuran solution (2.00mL,1.00mol/L) of lithium aluminum hydride, moving to room temperature after dropwise adding, stirring for 2 hours, then finishing the reaction, cooling the reaction liquid to 0 ℃, slowly dropwise adding 10mL of an ethyl acetate solution, and slowly dropwise adding methanol after dropwise adding: 2mL of a 10:1 solution of water, then the reaction solution was added dropwise to ice water, extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to give the title compound.
DMSO-d6δH 10.52(s,1H),7.38-7.37(m,1H),7.19-7.17(m,1H),7.00-6.91(m,2H),6.72-6.71(m,1H),6.12-6.09(m,2H),5.26-5.23(m,1H),5.05(s,1H),4.83-4.79(m,0.5H),4.66-4.63(m,0.5H),3.96-3.93(m,1H),3.69-3.60(m,3H),3.47-3.37(m,2H),3.14-3.03(m,1H),2.85-2.80(m,3H),2.64-2.50(m,3H),2.47-2.42(m,1H),1.07-1.06(m,3H),0.89-0.85(m,1H),0.79-0.73(m,1H),0.60-0.50(m,1H).
LC/MS(m/z,MH+):535.2
Example 2: 3- (((1R, 3R) -1- (2, 6-difluoro-4- ((1- ((((1S, 2S) -2-fluorocyclopropyl) methyl) azetidin-3-yl) amino) phenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000132
The title compound was obtained in a similar manner to example 1 except that (1R, 2R) -2-fluorocyclopropane-1-carboxylic acid in step 6 in example 1 was replaced with (1S, 2S) -2-fluorocyclopropane-1-carboxylic acid and the last two reactions of example 1 were carried out.
DMSO-d6δH 10.50(s,1H),7.38-7.36(m,1H),7.19-7.17(m,1H),7.00-6.91(m,2H),6.70-6.68(m,1H),6.11-6.08(m,2H),5.25-5.20(m,1H),5.05(s,1H),4.82-4.78(m,0.5H),4.65-4.62(m,0.5H),3.95-3.92(m,1H),3.69-3.60(m,3H),3.47-3.37(m,2H),3.14-3.03(m,1H),2.85-2.80(m,3H),2.64-2.50(m,3H),2.47-2.42(m,1H),1.07-1.05(m,3H),0.91-0.85(m,1H),0.79-0.71(m,1H),0.59-0.49(m,1H).
LC/MS(m/z,MH+):535.2
Example 3: 3- (((1R, 3R) -1- (2, 6-difluoro-4- ((1- ((((1S, 2R) -2-fluorocyclopropyl) methyl) azetidin-3-yl) amino) phenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000141
The title compound was obtained in a similar manner to example 1 except that (1R, 2R) -2-fluorocyclopropane-1-carboxylic acid in step 6 in example 1 was replaced with (1S, 2R) -2-fluorocyclopropane-1-carboxylic acid and the last two reactions of example 1 were carried out.
DMSO-d6δH 10.51(s,1H),7.38-7.35(m,1H),7.19-7.17(m,1H),7.00-6.91(m,2H),6.70-6.68(m,1H),6.11-6.08(m,2H),5.25-5.20(m,1H),5.05(s,1H),4.82-4.78(m,0.5H),4.65-4.62(m,0.5H),3.95-3.92(m,1H),3.69-3.60(m,3H),3.47-3.37(m,2H),3.14-3.03(m,1H),2.85-2.80(m,3H),2.64-2.49(m,3H),2.47-2.42(m,1H),1.07-1.05(m,3H),0.91-0.85(m,1H),0.79-0.71(m,1H),0.59-0.49(m,1H).
LC/MS(m/z,MH+):535.2
Example 4: 3- ((1R, 3R) -1- (4- ((1- ((2, 2-difluorocyclopropyl) methyl) azetidin-3-yl) amino) -2, 6-difluorophenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000142
The title compound was obtained in a similar manner to example 1 except that (1R, 2R) -2-fluorocyclopropane-1-carboxylic acid in step 6 of example 1 was replaced with 2, 2-difluorocyclopropane-1-carboxylic acid and the last two reactions of example 1 were carried out in the same manner.
DMSO-d6δH 10.51(s,1H),7.38-7.36(m,1H),7.19-7.17(m,1H),7.00-6.91(m,2H),6.71-6.70(m,1H),6.12-6.09(m,2H),5.25-5.22(m,1H),5.05(s,1H),3.98-3.90(m,1H),3.71-3.60(m,3H),3.47-3.38(m,2H),3.14-3.03(m,1H),2.83-2.80(m,3H),2.68-2.55(m,3H),2.43-2.38(m,1H),1.75-1.62(m,1H),1.57-1.48(m,1H),1.20-1.12(m,1H),1.07-1.06(m,3H).
LC/MS(m/z,MH+):553.2
Example 5: 3- ((1R, 3R) -1- (4- ((1- ((3, 3-difluorocyclobutyl) methyl) azetidin-3-yl) amino) -2, 6-difluorophenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyridinyl [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000143
The title compound was obtained in a similar manner to example 1 except that (1R, 2R) -2-fluorocyclopropane-1-carboxylic acid in step 6 of example 1 was replaced with 3, 3-difluorocyclobutane-1-carboxylic acid and the last two reactions of example 1 were carried out in the same manner.
DMSO-d6δH 10.51(s,1H),7.38-7.36(m,1H),7.19-7.17(m,1H),7.08-6.91(m,2H),6.69-6.68(m,1H),6.12-6.08(m,2H),5.24-5.21(m,1H),5.05(s,1H),3.97-3.90(m,1H),3.72-3.62(m,3H),3.49-3.36(m,3H),3.13-3.03(m,1H),2.84-2.77(m,3H),2.68-2.55(m,4H),2.27-2.15(m,3H),2.08-2.06(m,1H),1.07-1.06(m,3H).
LC/MS(m/z,MH+):567.2
Example 6: 3- ((1R, 3R) -1- (2, 6-difluoro-4- ((1- ((3-fluorocyclobutyl) methyl) azetidin-3-yl) amino) phenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000151
The title compound was obtained in a similar manner to example 1 except that (1R, 2R) -2-fluorocyclopropane-1-carboxylic acid in step 6 of example 1 was replaced with 3-fluorocyclobutanecarboxylic acid and the last two reactions of example 1 were carried out in the same manner.
DMSO-d6δH 10.51(s,1H),7.38-7.36(m,1H),7.19-7.17(m,1H),7.00-6.91(m,2H),6.69-6.67(m,1H),6.11-6.08(m,2H),5.24-5.21(m,1H),5.05(s,1H),3.95-3.90(m,1H),3.72-3.62(m,4H),3.43-3.36(m,3H),3.13-3.03(m,1H),2.84-2.77(m,3H),2.68-2.55(m,4H),2.27-2.15(m,3H),2.08-2.06(m,1H),1.07-1.05(m,3H).
LC/MS(m/z,MH+):549.2
Example 7: 3- (((1R, 3R) -1- (2, 6-difluoro-4- (((S) -1- ((((1S, 2S) -2-fluorocyclopropyl) methyl) pyrrolidin-3-yl) amino) phenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyridine [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000152
The title compound was obtained in analogy to example 1, except that the last six steps of example 1 were carried out in analogy to example 1, substituting 1-tert-butoxycarbonyl-3-aminocyclobutylamine for (S) -3-aminopyrrolidine-1-carboxylic acid tert-butyl ester in step 2 of example 1.
DMSO-d6δH 10.51(s,1H),7.38-7.36(m,1H),7.19-7.17(m,1H),7.00-6.91(m,2H),6.22-6.19(m,3H),5.25-5.22(m,1H),5.03(s,1H),4.85-4.81(m,0.5H),4.68-4.64(m,0.5H),3.76-3.62(m,2H),3.46-3.36(m,2H),3.12-3.02(m,2H),2.83-2.78(m,1H),2.70-2.60(m,3H),2.46-2.38(m,4H),1.07-1.05(m,3H),0.82-0.57(m,5H).
LC/MS(m/z,MH+):549.2
Example 8: 3- ((1R, 3R) -1- (2, 6-difluoro-4- (((S) -5- ((((1R, 2R) -2-fluorocyclopropyl) methyl) -5-azaspiro ] [2.4] heptan-7-yl) amino) phenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol
Figure BDA0003234344130000161
The title compound was obtained in a similar manner to example 1 except that 1-tert-butoxycarbonyl-3-aminocyclobutylamine in step 2 of example 1 was replaced with tert-butyl (S) -7-amino-5-azaspiro [2.4] heptane-5-carboxylate by the latter six-step reaction of example 1.
DMSO-d6δH 10.51(s,1H),7.38-7.36(m,1H),7.19-7.17(m,1H),7.00-6.91(m,2H),6.22-6.19(m,3H),5.25-5.22(m,1H),5.03(s,1H),4.85-4.81(m,0.5H),4.68-4.64(m,0.5H),3.76-3.62(m,2H),3.46-3.36(m,2H),3.12-3.02(m,2H),2.83-2.78(m,1H),2.70-2.54(m,4H),2.46-2.38(m,3H),1.07-1.05(m,3H),1.00-0.94(m,1H),0.81-0.71(m,2H),0.65-0.41(m,4H).
LC/MS(m/z,MH+):575.2
Example 9: n- (1- ((((1R, 2R) -2-fluorocyclopropyl) methyl) azetidin-3-yl) -6- ((6S, 8R) -8-methyl-7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinolin-6-yl) pyridin-3-amine
Figure BDA0003234344130000162
Step 1: synthesis of tert-butyl 3- ((6- ((6S, 8R) -8-methyl-3- (tetrahydro-2H-pyran-2-yl) -7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinolin-6-yl) pyridin-3-yl) amino) azetidine-1-carboxylate
Figure BDA0003234344130000171
The intermediate (6S, 8R) -6- (5-bromopyridin-2-yl) -8-methyl-3- (tetrahydro-2H-pyran-2-yl) -7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinoline was prepared according to the procedure of WO2018077630a1, example 17.
(6S, 8R) -6- (5-bromopyridin-2-yl) -8-methyl-3- (tetrahydro-2H-pyran-2-yl) -7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinoline (5.08g, 10.0mmol), 1-tert-butoxycarbonyl-3-aminocyclobutylamine (2.06g, 12.0mmol), tris (dibenzylideneacetone) dipalladium (458mg, 0.5mmol), 4, 5-bis-diphenylphosphine-9, 9-dimethylxanthene (579mg, 1.00mmol), cesium carbonate (9.75g,30.0mmol) were added to 40mL1, 4-dioxane, and the reaction was completed after heating to 80 ℃ under argon protection and stirring for 6 hours, and concentrating the reaction solution, adding 100mL of ethyl acetate, performing suction filtration, and concentrating the filtrate to obtain a crude product.
Step 2: synthesis of N- (azetidin-3-yl) -6- (((6S, 8R) -8-methyl-7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4], 3-f ] isoquinolin-6-yl) pyridin-3-amine
Figure BDA0003234344130000172
Dissolving tert-butyl 3- ((6- ((6S, 8R) -8-methyl-3- (tetrahydro-2H-pyran-2-yl) -7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinolin-6-yl) pyridin-3-yl) amino) azetidine-1-carboxylate (600mg, 1.00mmol) in 30mL of methanol, cooling to 0 ℃, slowly adding a 4M/L hydrogen chloride dioxane solution (2.50mL, 10.0mmol), after the completion of the addition, moving to room temperature, stirring for 2 hours, cooling the reaction solution to 0 ℃, slowly adding a saturated sodium bicarbonate aqueous solution, adjusting the pH to 8-9, after addition of 150mL of water, extraction was performed with ethyl acetate, and the organic layers were combined, dried over anhydrous sodium sulfate, filtered with suction and concentrated to give the title compound.
And step 3: synthesis of ((1R, 2R) -2-fluorocyclopropyl) (3- ((6- ((6S, 8R) -8-methyl-7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinolin-6-yl) pyridin-3-yl) amino) azetidin-1-yl) methanone
Figure BDA0003234344130000173
N- (azetidin-3-yl) -6- (((6S, 8R) -8-methyl-7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4], 3-f ] isoquinolin-6-yl) pyridin-3-amine (416mg, 1.00mmol), 2- (7-azabenzotriazole) -N, N, N ', N' -tetramethylurea hexafluorophosphate (380mg, 1.00mmol), (1R, 2R) -2-fluorocyclopropane-1-carboxylic acid (104mg, 1.00mmol) was dissolved in 30mL of N, N-dimethylformamide, N, N-diisopropylethylamine (258mg, 2.00mmol) was added thereto, and the reaction was allowed to proceed to completion after stirring at room temperature for 1 hour, the reaction solution was added to 100mL of water, extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to give the title compound.
And 4, step 4: synthesis of N- (1- ((((1R, 2R) -2-fluorocyclopropyl) methyl) azetidin-3-yl) -6- ((6S, 8R) -8-methyl-7- (2,2, 2-trifluoroethyl) -6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinolin-6-yl) pyridin-3-amine
Figure BDA0003234344130000181
(3- ((4- ((1R, 3R) -2- (2, 2-difluoro-3-hydroxypropyl) -3-methyl-2, 3,4, 9-tetrahydro-1H-pyridinyl [3,4-b ] indol-1-yl) -3, 5-difluorophenyl) amino) azetidin-1-yl) ((1R, 2R) -2-fluorocyclopropyl) methanone (250mg, 0.50mmol) was added to 10mL anhydrous tetrahydrofuran, cooling to 0 ℃, slowly dropwise adding a tetrahydrofuran solution (1.00mL,1.00M/L) of borane, moving to 70 ℃ after dropwise adding, heating and stirring for 2 hours, then finishing reaction, cooling the reaction liquid to 0 ℃, adding 20mL of methanol, concentrating, and carrying out column chromatography to obtain the title compound.
DMSO-d6δH 13.02(s,1H),8.06(s,1H),7.79-7.78(m,1H),7.24-7.22(m,1H),7.06-7.04(m,1H),6.98-6.96(m,1H),6.80-6.78(m,1H),6.58-6.56(m,1H),4.96(s,1H),4.52-4.51(m,0.5H),4.35-4.34(m,0.5H),3.95(m,1H),3.64-3.60(m,2H),3.55-3.45(m,2H),3.09-3.04(m,1H),3.00-2.94(m,1H),2.87-2.81(m,1H),2.74-2.71(m,2H),2.47-2.41(m,2H),1.07-1.06(m,3H),0.98-0.82(m,3H).
LC/MS(m/z,MH+):489.2。
Examples of biological Activity and related Properties
Experimental example 1: detection of degradation effect of compound of the invention on MCF7 intracellular estrogen receptor
The test principle is as follows: determination of the degradative Activity of the Compounds of the invention on endogenously expressed Estrogen receptors in MCF7 cells, according to IC50And evaluation of maximum degradation efficiencyThe activity of the test compound.
The test method comprises the following steps:
MCF7 cells (purchased from ATCC, HTB-22) were cultured in DMEM (purchased from Gibco, 11995-. The first day of experiment, MCF7 cells were seeded at 3000 cells/well in 384-well plates at 37 ℃ with 5% CO using complete medium2And (5) culturing in a cell culture box. Test compounds were dissolved in DMSO at a stock concentration of 10mM, diluted with Echo550 (available from Labcyte Inc.) and added to the cell culture plate, each compound treatment was initiated at 100nM, diluted in a 3-fold gradient, 9 concentration points, a blank containing 0.5% DMSO was set up, and a duplicate well control was set up for each concentration point. 37 ℃ and 5% CO2The cell culture box was cultured for 24 hours. Adding paraformaldehyde into each cell culture well, fixing cells at a final concentration of about 3.7%, reacting for 30min, removing supernatant, and washing with 50 μ L PBS once per well; the cells were treated for 30 minutes with PBS (containing 0.5% v/v Tween-20) and washed once with PBS; adding blocking solution (self-made, 5% BSA and 0.05% v/v Tween-20 in PBS) and incubating for 1 hour at room temperature; removing the blocking solution, adding primary antibody mixture (anti-ER monoclonal antibody, Estrogen Receptor alpha (D8H8) Rabbit mAb purchased from GST, #8644S, diluted at 1: 1000; anti-GAPDH monoclonal antibody, GAPDH (D4C6R) Mouse mAb purchased from GST, #97166S, diluted at 1: 2000) and incubating at room temperature for 3 hours; washing 3 times with PBST (homemade, PBS containing 0.05% v/v Tween-20); adding a detection secondary antibody (800 CW-goat anti-rabbit IgG, purchased from LI-COR, P/N:926-32211, diluted 1: 1000; 680 RD-goat anti-mouse IgG, purchased from LI-COR, #925-68070, diluted 1: 1000), and incubating for 45 minutes at room temperature in a dark place; PBST was washed 3 times and the fluorescence signal from each well was read using the Odyssey CLx. XLFit was used for data processing, and the inhibitory activity IC of each compound was calculated from the concentration of the compound and the fluorescence signal value50And maximum degradation efficiency.
And (3) test results:
under the present experimental conditions, the test compounds have good inhibitory activity against ER level at a cell-based level. The results of the ER level activity assay for the test compounds are shown in Table 1.
TABLE 1 results of in vitro cell-level-based ER level Activity assay for test Compounds
Test compounds ER level DC50(nM) Maximum ER Down-Regulation (%)
Example 1 0.07 103.36
Example 2 0.14 95.76
Example 3 0.45 79.50
Example 4 0.12 95.84
Example 5 0.36 90.21
Example 6 0.23 84.93
Example 7 0.22 90.95
Example 8 0.31 95.37
Example 9 0.22 107.81
Experimental example 2: examination of inhibitory Effect of the Compound of the present invention on proliferation of T47D cells
The test principle is as follows: determining the inhibitory Effect of the Compounds of the invention on the in vitro proliferation of T47D cells, according to IC50The activity of the compounds was evaluated.
The test method comprises the following steps:
T47D (T-47D) cells (purchased from ATCC, HTB-133) were cultured in RPMI-1640 (purchased from Gibco, A10491-01) complete medium containing 10% fetal bovine serum. On the first day of experiment, T47D cells were seeded at a density of 500 cells/well in 384-well plates at 37 ℃ with 5% CO using complete medium2The cell culture box was cultured overnight. The next day, test compound was added for drug treatment, and a10 mM stock solution of each compound was diluted with Echo550 (available from labcell Inc.) and transferred to each cell culture well at an initial intracellular treatment concentration of 100nM, 3-fold gradient dilution, 10 concentration points, a blank containing 0.3% DMSO was set, and a duplicate well control was set for each concentration point. 37 ℃ and 5% CO2The cell culture box is used for 7 days, and on the eighth day, the cell culture plate is taken out. Adding into
Figure BDA0003234344130000191
Luminescennt Cell visual Assay (available from Promega, G7573) was allowed to stand at room temperature for 10 minutes, and then the luminescence signal value was read using a multi-label microplate reader EnVision (available from PerkinElmer), and the inhibitory activity IC of each compound was calculated from the concentration of the compound and the luminescence signal value using XLfit50
And (3) test results:
under the conditions of this experiment, the test compound showed good inhibitory activity against T47D breast cancer cells. The results of the inhibitory activity of the test compounds on T47D cell proliferation are detailed in table 2.
TABLE 2 inhibitory Activity of Compounds on T47D cell proliferation
Test compounds T47D IC50(nM)
Example 1 0.17
Experimental example 3: examination of inhibitory Effect of the Compound of the present invention on MCF7 cell proliferation
The test principle is as follows: determining the inhibitory Effect of the Compounds of the invention on the in vitro proliferation of MCF7 cells, according to IC50And maximum inhibition efficiency to evaluate the activity of the compound.
The test method comprises the following steps:
MCF7 cells (ATCC, HTB-22) were cultured in DMEM (Gibco, 11995-065) complete medium containing 10% fetal bovine serum. The first day of experiment, MCF7 cells were seeded at a density of 500 cells/well in 384-well plates at 37 ℃ with 5% CO using complete medium2The cell culture box was cultured overnight. The next day, test compound was added for drug treatment, and a compound solution with a stock concentration of 10mM was diluted with Echo550 (labcell Inc.) and transferred to each cell culture well, with the start concentration of each compound in the cells being 100nM, 3-fold gradient dilution, 9 concentration points, a blank containing 0.3% DMSO was set, and a duplicate well control was set for each concentration point. 37 ℃ and 5% CO2The cell culture box is used for 7 days, and on the eighth day, the cell culture plate is taken out. Adding into
Figure BDA0003234344130000192
Luminescent Cell visual Assay (Promega, G7573), left at room temperature for 10 minutes, the luminescence signal value was read using a multi-label microplate reader envision (perkinelmer), and the inhibitory activity IC of each compound was calculated from the concentration of the compound and the luminescence signal value using XLfit50
And (3) test results:
under the experimental condition, the test compound has better inhibitory activity on MCF-7 cell proliferation. The results are shown in Table 3.
TABLE 3 inhibitory Activity of Compounds on MCF-7 cell proliferation
Compound numbering MCF-7 cell proliferation inhibition IC50(nM)
Example 1 0.07
Experimental example 4: pharmacokinetic Property testing of Compounds of the invention
The test principle is as follows: the drug concentration in the blood plasma of the mice at different times after the mice are subjected to gastric lavage and intravenous administration of the compound is measured by an LC/MS/MS method by taking the mice as test animals. The pharmacokinetic behavior of the compounds of the invention in mice was studied and their pharmacokinetic profile was evaluated.
The test method comprises the following steps:
4.1 test animals
24 healthy adult BALB/c mice, female, were divided into 4 groups on average, 6 mice per group, 3 gavage, 3 veins, mice purchased from Beijing vitamin Tonglihua laboratory animal technology, Inc., animal production license number: SCXK (Zhe) 2019-.
4.2 pharmaceutical preparation
Weighing a certain amount of medicine, dissolving in DMSO 5% + PG 20% + absolute ethyl alcohol 5% + solutol 10% + water 60%, preparing into 10mg/ml, and using for intragastric administration. Weighing a certain amount of medicine, dissolving in DMSO 1% + PG 4% + absolute ethyl alcohol 1% + solutol 2% + water 92%, and preparing into 1mg/ml for intravenous injection.
4.3 administration of drugs
And (3) gastric lavage group: BALB/c mice were fasted overnight and then gavaged at a dose of 10mg/kg and a volume of 1 mL/kg.
Vein group: BALB/c mice were administered intravenously after overnight fasting at a dose of 1mg/kg and a volume of 1 mL/kg.
4.4 operation
After the mice are administrated by gastric lavage or intravenous injection, 40 mu L of blood collected from orbit 5min, 15min, 30min, 1h, 2h, 4h and 24h after the administration, 5 mu L of EDTA-K2 is anticoagulated, blood plasma is centrifugally separated at 12000rpm and 4 ℃ for 5 minutes, and the blood plasma is preserved at-20 ℃.
Determining the content of the compound to be tested in the plasma of the mouse after the drugs with different concentrations are administered by gastric lavage or vein: melting the sample at room temperature, and vortexing for 1 min; quantitatively transferring 15. mu.L to a 2ml 96-well plate, adding 150. mu.L of internal standard precipitant, and shaking (1200 rpm. times.3 min); centrifugation (4000rpm 15min) and transfer of 100. mu.L of supernatant into 1ml 96-well plates; blow-drying with nitrogen, adding 100. mu.L of the double solution (acetonitrile 1: 9), shaking (900 rpm. times.3 min), and analyzing 20. mu.L of the sample. LC/MS/MS conditions: mobile phase A, 0.1% aqueous formic acid, mobile phase B: 0.1% formic acid acetonitrile, column: ACE C185 μm (3.0mm x 50mm), column temperature: flow rate 0.5ml/min at 35 ℃.
And (3) test results:
under the conditions of the experiment, the tested compounds show better pharmacokinetic properties, and the results are shown in table 4.
TABLE 4 pharmacokinetic parameters after single gavage administration of Compounds in mice
Figure BDA0003234344130000201
The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiment. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims (13)

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure FDA0003234344120000011
wherein:
X1、X2、X3、X4independently selected from CR7Or N;
R7selected from H, F, Cl, Br, I, OH, CN, C1-C6Alkyl radical, C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C1-C6Alkoxy radical, C3-C6Cycloalkyloxy or 3-6 membered heterocycloalkyloxy;
het is selected from
Figure FDA0003234344120000012
R1、R2Independently selected from hydrogen, OH, F, Cl, Br, I, C1-C6Alkyl or C2-C8An alkenyl group;
or, R1、R2Together with the carbon atom to which they are attached form C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with RaSubstitution;
w is selected from the group consisting of C in linear or branched form1-C3An alkylene group;
R5is selected from C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with 1 or more groups selected from:F、Cl、Br、I、CN、OH、OCH3And SO2CH3
R6Selected from H, C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
R3Selected from H, CN, COOH, C (O) ORb、OC(O)Rb、CONH2、C(O)NRbRc、SO2Rb、SO2NRbRc、C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl radical, C3-C6Heterocycloalkyl radical, C6-C10Aryl or C5-C10Heteroaryl of said C1-C6Alkyl radical, C3-C6Cycloalkyl radical, C3-C6Heterocycloalkyl radical, C6-C10Aryl or C5-C10Heteroaryl is optionally substituted with 1 or more RdSubstitution;
R4selected from H, F, Cl, Br, I, OH, C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl or C3-C6Heterocycloalkyl radical of said C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl or C3-C6Heterocycloalkyl is optionally substituted with one or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
Ring Q is selected from C6-C10Aryl or 5-to 10-membered heteroaryl, said C6-C10Aryl or 5-10 membered heteroaryl optionally substituted with 1 or more R8Substitution;
R8selected from F, Cl, Br, I, OH, CN, COOH, C (O) ORb、OC(O)Rb、CONH2、C(O)NRbRc、NRcC(O)Rb、SO2Rb、SO2NRb、C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C6-C10Aryl or 5-to 10-membered heteroaryl, said C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C6-C10Aryl or 5-10 membered heteroaryl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, OH, CN, C1-C6Alkyl and C1-C6An alkoxy group;
Raselected from halogen, OH, CN, C1-6Alkyl radical, C1-6Alkoxy radical, C3-6Cycloalkyl or 3-6 membered heterocycloalkyl, said C1-6Alkyl radical, C1-6Alkoxy radical, C3-6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with halogen;
Rbis independently selected from C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, C6-C10Aryl or 5-10 membered heteroaryl;
Rcindependently selected from H, C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl, 3-6 membered heterocycloalkyl, C6-C10Aryl or 5-10 membered heteroaryl;
Rdindependently selected from F, Cl, Br, I, OH, CN, C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C1-C6Alkyl radical, C1-C6Alkoxy radical, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with 1 or more groups selected from F, Cl, Br, I or OH;
n is 0, 1 or 2.
2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (Ia) or a pharmaceutically acceptable salt thereof:
Figure FDA0003234344120000021
3. a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R is1、R2Together with the carbon atom to which they are attached form C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl optionally substituted with RaAnd (4) substitution.
4. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R is1、R2Independently selected from hydrogen, OH, F, Cl, Br, I, C1-C6Alkyl or C2-C8An alkenyl group.
5. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R is3Is selected from C1-C6Alkyl or C6-C10An aryl group; said C is1-C6Alkyl or C6-C10Aryl is optionally substituted by one or more RdSubstituted, RdIndependently selected from F, Cl, Br, OH or C optionally substituted with 1 or more groups selected from F, Cl, Br or OH1-C6An alkyl group.
6. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R is4Selected from C optionally substituted by F, Cl, Br or I1-C6An alkyl group.
7. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein W is selected from the linear form of C1-C3An alkylene group.
8. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R is5Is C3-C6Cycloalkyl radical, said C3-C6Cycloalkyl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
9. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (II) or a pharmaceutically acceptable salt thereof:
Figure FDA0003234344120000031
wherein X1、X2、X3、X4、Het、R3、R4And R6As defined in claim 1;
R10selected from H, C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl, said C1-C6Alkyl radical, C2-C8Alkenyl radical, C2-C4Alkynyl, C3-C6Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted with 1 or more groups selected from: F. cl, Br, I, CN, OH, OCH3And SO2CH3
10. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (III):
Figure FDA0003234344120000041
wherein X1、X2、X3、X4、Het、R3、R4And R6As defined in claim 1.
11. The compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein the compound is selected from one of the following structures:
Figure FDA0003234344120000042
Figure FDA0003234344120000051
Figure FDA0003234344120000061
12. a pharmaceutical composition comprising a compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
13. Use of a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of an estrogen receptor related disorder, preferably a tumor, further preferably breast cancer.
CN202110997502.6A 2020-08-28 2021-08-27 Estrogen receptor modulator compounds and uses thereof Active CN114105977B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020108866421 2020-08-28
CN202010886642 2020-08-28

Publications (2)

Publication Number Publication Date
CN114105977A true CN114105977A (en) 2022-03-01
CN114105977B CN114105977B (en) 2023-09-01

Family

ID=80441126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110997502.6A Active CN114105977B (en) 2020-08-28 2021-08-27 Estrogen receptor modulator compounds and uses thereof

Country Status (1)

Country Link
CN (1) CN114105977B (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108611A (en) * 2014-12-18 2017-08-29 豪夫迈·罗氏有限公司 Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof
US20170320871A1 (en) * 2016-04-08 2017-11-09 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US20180002344A1 (en) * 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN109311876A (en) * 2016-06-16 2019-02-05 豪夫迈·罗氏有限公司 heteroaryl estrogen receptor modulators and uses thereof
CN109843888A (en) * 2016-10-24 2019-06-04 阿斯利康(瑞典)有限公司 It can be used for the 6 for the treatment of cancer, 7,8,9- tetrahydro -3H- pyrazolo [4,3-f] isoquinilone derivatives
CN109843882A (en) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof
WO2019223715A1 (en) * 2018-05-23 2019-11-28 江苏恒瑞医药股份有限公司 Benzopiperidine or heteroarylpiperidine derivative, preparation method therefor, and medical application thereof
WO2020037203A2 (en) * 2018-08-17 2020-02-20 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
CN111499614A (en) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 Tetrahydroisoquinoline derivatives, preparation method and medical application thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108611A (en) * 2014-12-18 2017-08-29 豪夫迈·罗氏有限公司 Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof
US20170320871A1 (en) * 2016-04-08 2017-11-09 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US20180002344A1 (en) * 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN109311876A (en) * 2016-06-16 2019-02-05 豪夫迈·罗氏有限公司 heteroaryl estrogen receptor modulators and uses thereof
CN109843882A (en) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof
CN109843888A (en) * 2016-10-24 2019-06-04 阿斯利康(瑞典)有限公司 It can be used for the 6 for the treatment of cancer, 7,8,9- tetrahydro -3H- pyrazolo [4,3-f] isoquinilone derivatives
WO2019223715A1 (en) * 2018-05-23 2019-11-28 江苏恒瑞医药股份有限公司 Benzopiperidine or heteroarylpiperidine derivative, preparation method therefor, and medical application thereof
WO2020037203A2 (en) * 2018-08-17 2020-02-20 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
CN111499614A (en) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 Tetrahydroisoquinoline derivatives, preparation method and medical application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUN LIANG ET AL.,: "Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer", 《ACS MED. CHEM. LETT.》 *
JUN LIANG ET AL.,: "Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer", 《ACS MED. CHEM. LETT.》, vol. 11, no. 6, 26 May 2020 (2020-05-26), pages 1342 - 1347, XP093008663, DOI: 10.1021/acsmedchemlett.0c00224 *

Also Published As

Publication number Publication date
CN114105977B (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CN107428758B (en) Acrylic acid derivative, preparation method and medical application thereof
TW201930292A (en) Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
CN114423750B (en) 2, 4-Disubstituted pyrimidine derivative, preparation method and application thereof
WO2022135432A1 (en) Macrocyclic heterocyclic compounds as egfr inhibitors, and use thereof
CN106660974A (en) Sulfamyl-containing 1,2,5-oxadiazole derivative, preparation method therefor and use thereof in pharmaceuticals
WO2020007322A1 (en) Compound targeted to degrade bet protein and application thereof
JP7439018B2 (en) Substituted aryl ether compounds, their preparation methods, pharmaceutical compositions and their applications
EP3766882A1 (en) Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof
TW201910329A (en) Substituted five-membered and six-membered heterocyclic compound, preparation method thereof, pharmaceutical combination and use thereof
JP2021503443A (en) Antagonist of muscarinic acetylcholine receptor M4
CA3135070A1 (en) Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
WO2021238827A1 (en) Egfr inhibitor and preparation method and use thereof
EA032315B1 (en) Substituted tricyclic heterocyclic compounds
JP2020530451A (en) Antagonist of muscarinic acetylcholine receptor M4
CN115697987A (en) Estrogen receptor modulator compounds and uses thereof
CN111303133A (en) Small molecule compound for degrading EZH2 protein
CN113518779B (en) Thieno heterocyclic derivative, preparation method and medical application thereof
TW202110848A (en) A substituted fused bicyclic derivative, a preparation method thereof, and medical applications thereof
WO2022017365A1 (en) Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
JPWO2013147216A1 (en) (2-Heteroarylamino) succinic acid derivatives
CN115724857A (en) Aromatic heterocyclic compound, pharmaceutical composition containing same and application thereof
CN114105977B (en) Estrogen receptor modulator compounds and uses thereof
WO2021104413A1 (en) Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof
CN113896669A (en) Estrogen receptor modulators and uses thereof
CN108473504A (en) Novel dihydropyran hepyramine derivative and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230425

Address after: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311

Applicant after: Xiansheng Zaiming Pharmaceutical Co.,Ltd.

Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18

Applicant before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311

Patentee after: Hainan Xiansheng Zaiming Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311

Patentee before: Xiansheng Zaiming Pharmaceutical Co.,Ltd.

Country or region before: China